Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Axovant Sciences Ltd (AXON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Free Pre-Market Technical Recap on Axovant Sciences and Three Additional Biotech Stocks

Stock Research Monitor: BPMC, CASI, and PTI

AXON : 2.46 (-4.28%)
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.

AXON : 2.46 (-4.28%)
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

QURE : 34.09 (-4.24%)
SLDB : 43.11 (-2.27%)
AXON : 2.46 (-4.28%)
NVS : 82.27 (+1.82%)
BOLD : 41.43 (+1.92%)
PFE : 37.33 (-0.08%)
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

CELG : 85.10 (-0.28%)
IDRA : 0.86 (-1.15%)
AXON : 2.46 (-4.28%)
XLRN : 46.58 (+0.60%)
BIIB : 358.71 (+0.17%)
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.

QURE : 34.09 (-4.24%)
SLDB : 43.11 (-2.27%)
BNTC : 2.73 (-0.73%)
AXON : 2.46 (-4.28%)
Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant

Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it has licensed to Axovant Sciences ("Axovant") the exclusive global rights for BB-301...

AXON : 2.46 (-4.28%)
BNIKF : 0.1360 (-2.86%)
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.

QURE : 34.09 (-4.24%)
SLDB : 43.11 (-2.27%)
SRPT : 133.31 (-1.64%)
AXON : 2.46 (-4.28%)
Axovant to Present at First Annual Roivant Pipeline Day

Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m....

AXON : 2.46 (-4.28%)
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

AXON : 2.46 (-4.28%)
REGN : 367.11 (-0.17%)
AMGN : 190.49 (-0.66%)
ALXN : 135.16 (+0.05%)
BIIB : 358.71 (+0.17%)
Implied Volatility Surging for Axovant (AXON) Stock Options

Axovant (AXON) needs investors to pay close attention to the stock based on moves in the options market lately.

AXON : 2.46 (-4.28%)
Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher

Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.

AXON : 2.46 (-4.28%)
ACOR : 28.75 (-1.37%)
Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session

Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.

GHDX : 57.34 (-1.66%)
AXON : 2.46 (-4.28%)
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica

Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.

QURE : 34.09 (-4.24%)
ONCE : 81.25 (-1.01%)
AXON : 2.46 (-4.28%)
NVS : 82.27 (+1.82%)
Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's...

HTBX : 2.24 (-3.03%)
AXON : 2.46 (-4.28%)
57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS

Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Manufacturing remains the issue, and many companies turning to outsourced manufacturing...

BLUE : 180.35 (+0.78%)
ABEO : 14.35 (+1.06%)
AXON : 2.46 (-4.28%)
Thinking about buying stock in Axovant Sciences, Cronos Group, Micron, Netflix or AT&T?

InvestorsObserver issues critical PriceWatch Alerts for AXON, CRON, MU, NFLX, and T.

NFLX : 361.05 (-0.87%)
T : 31.10 (-0.54%)
AXON : 2.46 (-4.28%)
MU : 55.02 (-2.13%)
Look for Shares of Axovant Sciences to Potentially Pullback after Yesterday's 104.57% Rise

Axovant Sciences (NASDAQ:AXON) traded in a range yesterday that spanned from a low of $3.27 to a high of $4.64. Yesterday, the shares gained 104.6%, which took the trading range above the 3-day high...

AXON : 2.46 (-4.28%)
Stock to Watch: Axovant Sciences Up 93.1% (AXON)

Axovant Sciences (NASDAQ:AXON) is one of today's best performing low-priced stocks, up 93.1% to $3.38 on 11.6x average daily volume. Axovant Sciences has traded 16.6 million shares thus far today, vs....

AXON : 2.46 (-4.28%)
Axovant Licenses Investigational Gene Therapy for Parkinson's Disease from Oxford BioMedica and Announces Key Leadership Team Addition

-- Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant's 2018 pipeline expansion

ONCE : 81.25 (-1.01%)
AXON : 2.46 (-4.28%)
Axovant to Present at Two Upcoming Investor Conferences

Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at...

AXON : 2.46 (-4.28%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar